| Program | Indications | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|---|---|
| OV888/GV101 capsule & ROCK2 Platform* | ||||||||
Selective ROCK2 inhibitor Collaboration with | Brainstem cavernous malformations, undisclosed rare CNS indications | |||||||
| OV329 | ||||||||
GABA-aminotransferase inhibitor In-licensed from | Oral formulation for chronic treatment of epilepsies | |||||||
GABA-aminotransferase inhibitor In-licensed from | IV formulation for acute treatment of seizures | |||||||
| Drug | Indication | Stage |
|---|---|---|
| OV888/GV101 capsule & ROCK2 Platform* |
||
Selective ROCK2 inhibitor Collaboration with | Brainstem cavernous malformations, undisclosed rare CNS indications | Phase 2 |
| OV329 |
||
GABA-aminotransferase inhibitor In-licensed from | Oral formulation for chronic treatment of epilepsies | Phase 1 |
GABA-aminotransferase inhibitor In-licensed from | IV formulation for acute treatment of seizures | Preclinical |